What is Advicenne?
Advicenne operates as a high-impact specialty pharmaceutical entity dedicated to the research and development of innovative therapeutic solutions for rare kidney diseases. By focusing on the intersection of drug delivery technology and nephrology, the company addresses significant gaps in the current medical landscape. Their core competency lies in the reformulation of existing compounds to enhance safety and efficacy for both pediatric and adult demographics. This strategic focus on niche therapeutic areas allows Advicenne to navigate the complex regulatory environment of rare disease treatment while maintaining a lean, high-value development pipeline that prioritizes patient-centric outcomes over mass-market volume.
How much funding has Advicenne raised?
Advicenne has raised a total of $57.9M across 3 funding rounds:
Unspecified
$17.2M
Stock Offering
$36.4M
Debt
$4.3M
Unspecified (2017): $17.2M with participation from iXO Private Equity and Bpifrance and InnoBio
Stock Issuance/Offering (2017): $36.4M, investors not publicly disclosed
Debt (2026): $4.3M, investors not publicly disclosed
Key Investors in Advicenne
Bpifrance
A French public investment bank that supports companies at every stage of development through credit, guarantees, and equity, with a strong focus on innovation and international growth.
iXO Private Equity
An independent private equity firm based in France that specializes in providing growth capital to small and mid-cap companies across various industrial and service sectors.
InnoBio
A specialized venture capital fund managed by Bpifrance, focused on investing in innovative biotechnology companies that develop breakthrough medical treatments.
What's next for Advicenne?
The recent influx of capital positions Advicenne to accelerate its clinical development programs and expand its commercial footprint in the nephrology space. As the company transitions into a more mature enterprise-level lifecycle, the focus will likely shift toward scaling its manufacturing capabilities and navigating the final stages of regulatory approval for its lead candidates. By leveraging its expertise in drug delivery, Advicenne is well-positioned to secure a dominant market share in the rare renal disease segment, potentially attracting further strategic partnerships or acquisition interest from larger pharmaceutical conglomerates seeking to diversify their portfolios with high-barrier-to-entry therapeutic assets.
See full Advicenne company page
